Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 8,146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

NCT01380093
View directory record Official record
Conditions
Nondependent Opioid Abuse, Episodic
Interventions
Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage

NCT02934321
View directory record Official record
Conditions
Satiety in Healthy Volunteers
Interventions
Erythritol, Aspartame
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 4:21 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

NCT06205121
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
OATD-01, Placebo
Drug
Lead sponsor
Molecure S.A.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Kansas City, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia

NCT05179226
View directory record Official record
Conditions
Iron Deficiency, Anaemia in Children
Interventions
Ferric Derisomaltose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
Up to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

NCT00954226
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

NCT01847326
View directory record Official record
Conditions
Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Tongue Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, hydroxyurea, therapeutic conventional surgery, radiation therapy, hyperfractionated radiation therapy, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

NCT00540878
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689 oral tablets (400 mg)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 26, 2026, 4:21 AM EDT
Recruiting Phase 3 Interventional

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
Camizestrant, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

NCT05142592
View directory record Official record
Conditions
Safety Issues, Tolerability, Pharmacokinetics
Interventions
IPG7236
Drug
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

NCT06392711
View directory record Official record
Conditions
Xerostomia, Graft-versus-host-disease, Sjogren's Disease
Interventions
Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Terminated No phase listed Observational

Novel Technique for Face Mask Ventilation

NCT01946464
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 26, 2026, 4:21 AM EDT
Terminated Early Phase 1 Interventional

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

NCT03578432
View directory record Official record
Conditions
Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
Interventions
Everolimus, Laboratory Biomarker Analysis, Survey Administration
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 26, 2026, 4:21 AM EDT
Terminated Early Phase 1 Interventional

A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

NCT03427021
View directory record Official record
Conditions
GI Patients on Oxaliplatin Containing Regimen
Interventions
Oxaliplatin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

NCT01775904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY2886721 in a Capsule, LY2886721 in an orally disintegrating tablet (ODT)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 26, 2026, 4:21 AM EDT
Not yet recruiting Phase 4 Interventional

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

NCT07845552
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

NCT06710847
View directory record Official record
Conditions
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions
GSK4418959, PD-1 inhibitor
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

NCT05236738
View directory record Official record
Conditions
Healthy Participants
Interventions
Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Text-message Support to Improve Oral Antibiotic Adherence After ED Discharge

NCT01388465
View directory record Official record
Conditions
Medication Adherence
Interventions
Mobile phone text messaging
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

NCT00002506
View directory record Official record
Conditions
Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions
recombinant interferon alfa, isotretinoin
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1999
U.S. locations
6
States / cities
Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01103349
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo, Montelukast
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Addiction Treatment in Russia: Oral vs. Naltrexone Implant

NCT00218426
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
naltrexone implant, oral naltrexone, oral placebo naltrexone, placebo implant
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Trial of Parotid Sparing Whole Brain Radiation

NCT03595878
View directory record Official record
Conditions
Xerostomia
Interventions
Parotid sparing WBRT, Standard WBRT
Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 26, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023

NCT03542435
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SXC-2023, Placebo
Drug
Lead sponsor
Promentis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 26, 2026, 4:21 AM EDT